NASDAQ · ARTL

Artelo Biosciences, Inc.

$1.02 -$0.04 (-3.77%) 1D After hours
Session Pulse Overnight session 1 mentions on Tue No new SEC filings since Mon close its sector ranked 6/11 this week Full pulse →

Key Metrics

$3.69M
Market cap
P/E · TTM
Revenue · TTM
−$13.47M
Net income
EPS · TTM $-71.24
Dividend yield
Free cash flow
Beta · 1Y 1.24
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 21
    An insider transaction hit the record.

    Form 4s are events, not verdicts — officers, directors, and 10% owners reporting their own trades. The forms post hours before the media writes them up.

    RECEIPT: SEC FORM 4, TIMESTAMPED
  • Jul 17
    A material event was filed (Form 8-K).

    8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 8
    From its Mar 27 high, the share price fell 91%.

    Peak close $10.54 on Mar 27; trough close $1.00 on Jul 8. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -91%
  • Mar 27
    The stock moved +230.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 27
  • Mar 18
    The stock moved +50.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 18

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$3.69M
Enterprise value
Shares outstanding3.5M
52-wk range$0.96 – $19.91
Avg volume · 20D276.5K
Net cash
Book value / share$35.30
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Artelo Biosciences, Inc.
IPO dateOct 13, 2015
Employees7

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -282.6% · —

Financial Health

Current ratio1.79
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$4.59M

Cash Flow · TTM

Operating CF −$8.11M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings